Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Pevonedistat Plus Ibrutinib Showcases Preliminary Efficacy and Tolerability in CLL and MCL

October 21st 2021

The investigational NEDD8-activating enzyme inhibitor pevonedistat in combination with ibrutinib demonstrated high response rates with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Thompson on the Safety Profile of Pirtobrutinib in Patients With Richter Transformation

October 20th 2021

Meghan Thompson, MD, discusses the safety profile of pirtobrutinib in patients with Richter transformation.

Dr. Cheah on the Safety Profile of TG-1701 With and Without Ublituximab/Umbralisib in CLL

October 20th 2021

Chan Cheah, MBBS, discusses the toxicity profile of TG-1701 with and without ublituximab and umbralisib in patients with chronic lymphocytic leukemia.

Lisaftoclax Elicits Responses With a Tolerable Safety Profile in Relapsed/Refractory CLL

October 20th 2021

Sikander Ailawadhi, MD, discusses the unique pharmacodynamic profile of lisaftoclax, the similar responses seen across cohorts, and the favorable tolerability of the drug.

IGHV Mutation Status Now Included in clonoSEQ Diagnostic Assay in CLL

October 20th 2021

An upgraded model of the clonoSEQ® B-cell Clonality diagnostic tool has been released, which will now include IGHV mutation status for patients with chronic lymphocytic leukemia.

Dr. Ailawadhi on the Rationale for Evaluating Lisaftoclax in CLL

October 19th 2021

Sikander Ailawadhi, MD, discusses the rationale for evaluating lisaftoclax in chronic lymphocytic leukemia in an early phase 1 study.

Dr. Erba on Selecting Between Ibrutinib and Acalabrutinib in CLL

October 18th 2021

Harry Paul Erba, MD, PhD, discusses selecting between ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

FDA Grants Orphan Drug Designation to Bispecific Antibody LAVA-051 for CLL

October 18th 2021

The FDA has granted an orphan drug designation to LAVA-051, a CD1d-targeted Gammabody, for the treatment of patients with chronic lymphocytic leukemia.

Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL and Other Hematologic Malignancies

October 15th 2021

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia and other hematologic malignancies.

A Real-World Case of a Patient with CLL and a Cardiac History

October 15th 2021

Farrukh Awan shares a case of a patient with a cardiac history recently diagnosed with CLL requiring treatment.

Strategies for Managing Atrial Fibrillation in Patients on BTKi

October 15th 2021

Two experts discuss strategies for managing atrial fibrillation in patients with CLL on BTKi therapy.

Dr. Danilov on the Rationale to Combine Entospletinib With Obinutuzumab in CLL

October 14th 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Entospletinib Plus Obinutuzumab Shows Early Efficacy, Tolerability in High-Risk Relapsed/Refractory CLL

October 13th 2021

Alexey Danilov, MD, PhD, discussed the data on entospletinib/obinutuzumab in patients with R/R CLL and suggests further research directions with this drug combination.

Balancing the Risk and Benefit of Anticoagulation in Patients on BTKi

October 7th 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, review the risk versus benefit of anticoagulation strategies in patients on BTKi.

Baseline Testing Prior to Initiation of BTKi Treatment in CLL

October 7th 2021

Drs Lenneman and Awan discuss baseline testing before choosing a treatment strategy for battling chronic lymphocytic leukemia.

Key Safety Considerations

October 7th 2021

Two experts discuss key safety considerations when treating patients with chronic lymphocytic leukemia.

A Review of Treatment Options in CLL

October 7th 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, give an overview of chronic lymphocytic leukemia, the standard of care for treatment, and the current and emerging BTK inhibitors used to treat CLL.

Frontline Ibrutinib Shows Sustained Survival Advantage Over Chlorambucil in CLL at 7 Years

October 6th 2021

Tadeusz Robak, MD, discussed the 7-year safety and efficacy data from the RESONATE-2 trial examining frontline ibrutinib in CLL.

Frontline Acalabrutinib Plus Venetoclax/Obinutuzumab Shows Promising Activity in CLL

September 29th 2021

The frontline triplet combination comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be highly active and well tolerated when used in the treatment of patients with chronic lymphocytic leukemia.

Dr. Wierda on the Safety and Efficacy Results of the TRANSCEND CLL 004 Trial in CLL

September 23rd 2021

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.